AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
174.83
+2.89 (+1.68%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close171.94
Open173.66
Bid173.85 x 200
Ask175.89 x 100
Day's Range170.34 - 175.44
52 Week Range152.16 - 201.23
Volume4,693,756
Avg. Volume5,316,220
Market Cap116.834B
Beta1.71
PE Ratio (TTM)64.99
EPS (TTM)2.69
Earnings DateApr 24, 2018 - Apr 30, 2018
Forward Dividend & Yield5.28 (3.08%)
Ex-Dividend Date2018-05-16
1y Target Est195.14
Trade prices are not sourced from all markets
  • GlobeNewswire6 hours ago

    Biocartis Group NV: BIOCARTIS Q1 2018 BUSINESS UPDATE

    PRESS RELEASE:  REGULATED INFORMATION   Thursday, 26 April 2018, 07:00 CEST BIOCARTIS Q1 2018 BUSINESS UPDATE   Mechelen, Belgium , 26 April 2018 - Biocartis Group NV (the `Company` or `Biocartis`), an ...

  • Thomson Reuters StreetEvents13 hours ago

    Edited Transcript of AMGN earnings conference call or presentation 24-Apr-18 9:00pm GMT

    Q1 2018 Amgen Inc Earnings Call

  • Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
    Zacks14 hours ago

    Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

    The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

  • Benzinga16 hours ago

    Benzinga's Top Analyst Calls From April 25, 2018

    Cowen out positive following Amgen Inc (NASDAQ: AMGN ) earnings, calling it one of the better financial reports for the co. in some time; Says the stock is inexpensive and could benefit from significant ...

  • Barrons.com18 hours ago

    Biotech Bounceback: Amgen, Biogen Gain Believers

    On another down day for the market, biotech is a bright spot: Shares of Amgen (AMGN) have reversed earlier losses after reporting first-quarter earnings, and Biogen (BIIB) is rising. Amgen said it earned $3.47 a share on revenue of $5.55 billion, while analysts were looking for EPS of $3.25 on revenue of $5.44 billion. Credit Suisse's Alethia Young reiterated a Neutral rating Amgen, but she has a $194 price target, comfortably above the stock's current levels.

  • Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18
    Market Realist20 hours ago

    Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18

    In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.

  • Reutersyesterday

    Amgen expects strong demand for new migraine prevention drug

    Amgen Inc on Tuesday reported a higher first-quarter profit, as sales rose 3 percent - a trend it expects to accelerate as it launches new drugs like migraine treatment Aimovig, likely to get U.S. approval next month. Questions have been raised about Amgen's strategy for Aimovig after the nation's largest manager of prescription benefits, Express Scripts, told Reuters it is pressing Amgen and rival makers of new migraine-preventing drugs to reconsider the usual strategy of high list prices and hefty rebates. Shares of Amgen, which fell nearly 2 percent in earlier trading, were flat at $171.80 after hours.

  • Reuters2 days ago

    Amgen posts higher 1st-qtr profit as sales rise 3 pct

    Amgen Inc on Tuesday reported a higher first-quarter profit, driven by lower taxes and a 3 percent increase in product sales as growth for newer drugs like cholesterol medication Repatha offset weakness in older products. Shares of Amgen, which fell nearly 2 percent in earlier trading, were down another 1 percent at $170.01 after hours. Repatha sales, which more than doubled to $123 million, were higher than Wall Street expected, but the product "still has a long way to go to restore confidence that it has multi-billion-dollar sales potential," JP Morgan analyst Cory Kasimov said in a research report.

  • Amgen's 'Ho-Hum' Quarter Offers Wide Beat, Though Outlook Soft
    Investor's Business Daily2 days ago

    Amgen's 'Ho-Hum' Quarter Offers Wide Beat, Though Outlook Soft

    Amgen on Tuesday reported adjusted income of $3.47 per share on sales of $5.55 billion for its first quarter.

  • Associated Press2 days ago

    Amgen: 1Q Earnings Snapshot

    The Thousand Oaks, California-based company said it had net income of $3.25 per share. Earnings, adjusted for non-recurring costs, came to $3.47 per share. The results exceeded Wall Street expectations. ...

  • InvestorPlace2 days ago

    Amgen, Inc. (AMGN) Beats Q1 Estimates, Posts Weak F18 Guidance

    Amgen, Inc. (NASDAQ:AMGN) impressed in its quarterly earnings and revenue results, but the company’s stock did not rise much after hours due to a weak full-year guidance.

  • Amgen's Key New Drug Beats Estimates After Two Quarterly Misses
    Bloomberg2 days ago

    Amgen's Key New Drug Beats Estimates After Two Quarterly Misses

    Amgen Inc. offered some signs of optimism after disappointing results in recent months. Repatha received a new label in December from U.S. regulators after a study showed it reduced heart risks -- though not as much as some had expected -- and Amgen hoped it might expand patients’ access to the drug. Like other large biotechnology companies, Amgen must find new drivers of growth in the next few years as its blockbusters age -- making Repatha a key focus for investors.

  • MarketWatch2 days ago

    Amgen shares rise after company reports better-than-expected profit, sales

    Amgen Inc. shares rose more than 1% late Tuesday after the company reported first-quarter sales and profit above Wall Street expectations and revised its guidance. Amgen said it earned $2.31 billion, or $3.25 a share, in the quarter, compared with $2.07 billion, or $2.79 a share, in the year-ago period. Adjusted for one-time items, Amgen earned $2.46 billion, or $3.47 a share, compared with $2.33 billion, or $3.15 a share, a year ago.

  • PR Newswire2 days ago

    Amgen Reports First Quarter 2018 Financial Results

    THOUSAND OAKS, Calif. , April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include: Total revenues increased 2 percent versus ...

  • InvestorPlace2 days ago

    Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?

    It’s a busy week for pharmaceutical companies, with Eli Lilly And Co (NYSE:LLY), Biogen Inc (NASDAQ:BIIB), and Amgen, Inc. (NASDAQ:AMGN) having released their earnings report today. For Eli Lilly stock, investors sought a definitive sign where the renowned firm was headed. Since early summer of 2015, Eli Lilly stock gyrated wildly between bullish and bearish phases, only to come out dead even.

  • Reuters2 days ago

    Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc (AMGN.O), Eli Lilly and Co (LLY.N) and other makers of new migraine medicines to try and fix it. Express Scripts (ESRX.O) told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
    Reuters2 days ago

    Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

    By Deena Beasley LOS ANGELES (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc , Eli Lilly and Co and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist2 days ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • Reuters2 days ago

    Express Scripts targets new migraine drugs to change U.S. pricing dynamic

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Reuters2 days ago

    FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Better Buy: Amgen Inc. vs. Celgene
    Motley Fool2 days ago

    Better Buy: Amgen Inc. vs. Celgene

    How these two big biotechs compare in three key areas.

  • Financial Times2 days ago

    [$$] Amgen earnings boosted by new products, lower tax rate

    Amgen, the world’s largest biotech company, saw revenue inch higher in the first three months of 2018, with strong growth for recently launched products like its Repatha cholesterol medication softening a decline in sales of some of its more established ones. The company’s shares were little changed in after-hours trading on Tuesday following the report, which showed a 2 per cent gain in revenue from a year earlier to $5.6bn. Net income jumped 12 per cent to $2.3bn for the three months ending March 31, while earnings per share came in 16 per cent higher year-on-year to $3.25.

  • Alder BioPharmaceuticals poaches Amgen vet for new chief operating officer role
    American City Business Journals3 days ago

    Alder BioPharmaceuticals poaches Amgen vet for new chief operating officer role

    After 15 years at the global drug giant, Erin Lavelle will lead Alder's push to commercialize its migraine drug Eptinezumab.

  • Amgen beats the Street
    CNBC Videos2 days ago

    Amgen beats the Street

    CNBC's Meg Tirrell reports on the quarterly earnings for Amgen.

  • These stock could make big moves after their earnings rel...
    CNBC Videos2 days ago

    These stock could make big moves after their earnings rel...

    CNBC's Closing Bell news desk reports on stock performance for Amgen, Texas Instruments, and Wynn Resorts with data according to Kensho.